Accelerate Diagnostics Inc  

(Public, NASDAQ:AXDX)   Watch this stock  
Find more results for NYSEAMEX:AXK
-0.81 (-6.67%)
After Hours: 12.14 +0.81 (7.15%)
Feb 9, 4:06PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.29 - 12.13
52 week 10.29 - 31.29
Open 12.00
Vol / Avg. 0.00/410,807.00
Mkt cap 545.49M
P/E     -
Div/yield     -
EPS -0.92
Shares 44.74M
Beta 1.48
Inst. own 36%
Jan 12, 2016
Accelerate Diagnostics Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -12158.70% -25354.92%
Operating margin -12181.52% -25833.61%
EBITD margin - -25103.28%
Return on average assets -91.47% -54.64%
Return on average equity -100.22% -57.55%
Employees 73 -
CDP Score - -


3950 S. Country Club Road #470 Building 3-307
TUCSON, AZ 85714-2240
United States - Map
+1-303-8638088 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Accelerate Diagnostics, Inc. is an in-vitro diagnostics company providing solutions to improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. The Company is focused on reducing the failure rate of initial antibiotic drug therapy by shortening lab turnaround time to approximately five hours, rather than the two to three days required to deliver identification and susceptibility results. It has developed a diagnostic platform, the Accelerate ID/AST System (the ID/AST System), intended for the rapid diagnosis of infectious pathogens. The ID/AST System utilizes genotypic technology to identify (ID) infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. Accelerate Diagnostics UK Limited is a subsidiary of the Company.

Officers and directors

John Patience Independent Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Lawrence Mehren President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Steve Reichling Chief Financial Officer
Age: 36
Bio & Compensation  - Reuters
Ron Price Senior Vice President, Head - Commercial Operations
Bio & Compensation  - Reuters
Pete Bantock Chief Culture Officer, Head - Human Resources
Age: 49
Bio & Compensation  - Reuters
Mark C Miller Independent Director
Age: 59
Bio & Compensation  - Reuters
Jack W. Schuler Independent Director
Age: 74
Bio & Compensation  - Reuters
Matthew W. Strobeck Ph.D. Independent Director
Age: 42
Bio & Compensation  - Reuters
Frank J M ten Brink Independent Director
Age: 58
Bio & Compensation  - Reuters